Jump to content

Special Module lymphoma

About the Module

Although cutaneous lymphomas are rare, they can offer a significant diagnostic challenge for both the clinician and pathologist. This module presents a series of 15 clinical cases including images of histopathologic and immunohistochemical slides, the histological differential diagnosis, and an explanation of the reasoning that can help lead to the correct differential diagnosis. At the end of each case are a selection of clinical pearls - high yield notes about each lymphoma. At the end of this tutorial, participants will have gained an understanding of the diagnostic criteria for the most common cutaneous lymphomas.

About the Author

Dr Lyn McDivitt Duncan

Dr Lyn McDivitt Duncan received her MD and Anatomic Pathology training at Washington University School of Medicine in St. Louis and Dermatopathology Training at the MGH. She became a member of the MGH Dermatopathology Unit faculty in 1991, and has served at the Unit Chief since 2007.
Dr. Duncan serves on the Harvard/MIT Health Sciences and Technology Program Advisory Board and the Executive Committee of the Harvard Dermatopathology Training Program.With an expertise in the diagnosis of skin cancer, Dr. Duncan's research has led to revised classifications of cutaneous B-cell lymphoma and the identification of new biomarkers for malignant melanoma.
Dr. Duncan reported one of the first series of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type (MALT) in the skin and elucidated the diagnostic features that distinguish this tumor from benign lymphoid infiltrates. Dr. Duncan's contributions to the melanoma field include the discovery of the melanocyte specific biomarker Melastatin (TRPM1/MLSN), a prognostic factor for early stage melanoma, the development of a collaborative Skin SPORE tissue microarray platform that has been used internationally to evaluation melanoma biomarkers, and the development of a more sensitive analytical platform for melanoma detection in sentinel lymph nodes, in place at the MGH since 1995.
Dr. Duncan's current work is focused on the elucidation of prognostic factors including biomarkers and analytical platforms that inform patient care as predictors of patient outcome and response to therapy. Dr. Duncan's mission in the clinical realm is toward more efficient and cost-effective laboratory processing integrated with an expert consultative diagnostic service.

About the Author

Dr. Christopher Elco

Dr. Christopher Elco specializes in both dermatopathology and hematopathology. He completed his medical school training (MD/PhD program) at Case Western Reserve University in Cleveland, Ohio, USA along with his residency and hematopathology fellowship at Brigham and Womens Hospital in Boston,Massachusetts, USA. He subsequently served as a fellow in the combined Harvard Dermatopathology Program from 2012 to 2013.
At present, Dr Elco is conducting post-doctoral research at Brigham and Womens hospital. His interests lie in the diagnosis, classification, and pathogenesis of cutaneous hematologic malignancies, and innate immune signaling via Toll-like receptors in inflammatory and neoplastic diseases of the skin.

About the Author

Amrita Goyal

Amrita Goyal is a 4th year medical student at Harvard Medical School in the Harvard-MIT Health Sciences and Technology (HST) program. She graduated summa cum laude from Harvard College in 2010 with an undergraduate degree in Organismic and Evolutionary Biology. For the last year she has been conducting dermatopathology research at Massachusetts General Hospital under the supervision of Dr. Lyn Duncan. Amrita hopes to pursue a career in dermatology and dermatopathology.
  • Create New...